Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria

作者
Martin Inzinger,Katharina Wippel‐Slupetzky,Wolfgang Weger,Leo Richter,Alexander Mlynek,B Fleischander,Christine Scheurecker,N Sandor,Daniela Mairhofer,Paul Sator,S Moser-Oberthaler,N Häring,P Viznerova,Clemens Painsi,Adrian Tanew,P Ponholzer,Rafaella Tatarski,Winfried Brenner,G Stingl,Wolfgang Salmhofer
出处
期刊:Acta dermato-venereologica [Soc for Publication of Acta Dermato-Venereologica]
卷期号:96 (2): 207-212 被引量:40
标识
DOI:10.2340/00015555-2214
摘要

This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab. This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab. This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab. This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
hannah发布了新的文献求助10
2秒前
酷波er的应助被xun采纳,获得10
2秒前
2秒前
2秒前
3秒前
bkagyin的应助被撒拉嘿呀噻采纳,获得10
4秒前
Liu发布了新的文献求助30
4秒前
畅快访蕊完成签到,获得积分20
5秒前
优美的梦岚的应助被木叶流2022采纳,获得10
6秒前
7秒前
wanci的应助被路lu采纳,获得10
7秒前
ghost完成签到,获得积分10
8秒前
研友_VZG7GZ的应助被机智宛亦采纳,获得10
9秒前
kiluto发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
LynShen完成签到 ,获得积分20
10秒前
13秒前
13秒前
科研通AI65的应助被Mortal采纳,获得10
13秒前
13秒前
13秒前
为了精彩的活完成签到,获得积分10
13秒前
二三发布了新的文献求助10
14秒前
蒲公英完成签到 ,获得积分10
15秒前
哭泣雅绿发布了新的文献求助10
15秒前
英俊的铭的应助被动听的翠桃采纳,获得10
16秒前
hhh完成签到 ,获得积分20
17秒前
机灵语山完成签到,获得积分10
17秒前
wwwwww完成签到,获得积分10
17秒前
17秒前
huangping发布了新的文献求助20
17秒前
丘比特的应助被联网中请稍等采纳,获得10
18秒前
18秒前
充电宝的应助被Fern采纳,获得10
19秒前
Maestro_S的应助被鱼鱼鱼采纳,获得10
19秒前
123关闭了123的文献求助
20秒前
西柚宝宝完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192723
求助须知:如何正确求助?哪些是违规求助? 9579144
关于积分的说明 21863903
捐赠科研通 7792268
什么是DOI,文献DOI怎么找? 3437013
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483864